Tratamiento del linfoma no-hodgkin difuso en pacientes con la infección por el virus de inmunodeficiencia humana con ciclofosfamida-doxorubicina-vincristina-prednisona (CHOP) reporte final

Hernández, Dimas; Pérez, José; Somoza, Rosa.
Rev. venez. oncol ; 9(3): 119-24, jul.-sept. 1997.
Artículo en Español | LILACS | ID: lil-203368

Documentos relacionados

  1. R-CHOP in DLBCL: priming for success.
  2. A case report of primary unilateral adrenal NK/T cell lymphoma: good clinical outcome with trimodality treatment.
  3. [Intravascular Large B-cell Lymphoma: a Clinical Analysis of 17 Cases].
  4. Limited-stage diffuse large B-cell lymphoma.
  5. Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial.
  6. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
  7. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
  8. Analysis of real-world data in patients with relapsed/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era.
  9. Allogeneic stem cell transplantation for mantle cell lymphoma-update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74).
  10. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma].